Conditions: Alzheimer's Disease Psychosis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 181
Healthy volunteers: no

Brief summary:
This study will evaluate the safety and efficacy of pimavanserin 40 mg compared to placebo in patients with Alzheimer's disease psychosis.

Detailed description:

Arms:
arm 1: Placebo, two tablets, once daily by mouth arm 2: Pimavanserin tartrate, 40 mg (two 20 mg tablets), once daily by mouth (equivalent to 34 mg free base pimavanserin)

Interventions: intervention 1: Pimavanserin tartrate intervention 2: Placebo
Intervention descriptions: intervention 1: Pimavanserin tartrate, 40 mg (two 20 mg tablets), once daily by mouth (equivalent to 34 mg free base pimavanserin) intervention 2: Placebo, two tablets, once daily by mouth

Protocol document: